Advances in tuberculosis vaccine strategies (original) (raw)

• Kochi, A. The global tuberculosis situation and the new control strategy of the World Health Organization 1991. Bull. World Health Organ. 79, 71?75 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hopewell, P. C. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management and control of tuberculosis. Clin. Infect. Dis. 15, 540?547 (1992).
  CAS PubMed Google Scholar
• Raviglione, M. C. et al. Tuberculosis trends in eastern Europe and the former USSR. Tuber. Lung Dis. 75, 400?416 (1994).
  CAS PubMed Google Scholar
• Maher, D. et al. Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance? Int. J. Tuberc. Lung Dis. 9, 123?127 (2005).
  CAS PubMed Google Scholar
• Bloom, B. R. & Fine, P. E. In Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 531?557 (American Society for Microbiology, Washington DC, 1994).
  Google Scholar
• Summary from the 6th Annual Conference of the International Union Against Tuberculosis and Lung Disease. (Chicago, 2001).
• Ormerod, L. P., Horsfield, N. & Green, R. M. Tuberculosis treatment outcome monitoring: Blackburn 1988?2000. Int. J. Tuberc. Lung Dis. 6, 662?665 (2002).
  CAS PubMed Google Scholar
• Sudre, P., ten Dam, G. & Kochi, A. Tuberculosis: a global overview of the situation today. Bull. World Health Organ. 70, 149?159 (1992).
  CAS PubMed PubMed Central Google Scholar
• Dolin, P. J., Raviglione, M. C. & Kochi, A. Global tuberculosis incidence and mortality during 1990?2000. Bull. World Health Organ. 72, 213?220 (1994).
  CAS PubMed PubMed Central Google Scholar
• Hopewell, P. et al. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15 (Suppl. 1), 296?306 (1992).
  Google Scholar
• Smith, P. G. & Moss, A. R. In Tuberculosis: Pathogenesis, Protection, and Control. (ed Bloom, B. R.) 47?59 (American Society for Microbiology, Washington DC, 1994).
  Google Scholar
• Kaufmann, S. H. & McMichael, A. J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature Med. 11 (Suppl. 4), 33?44 (2005).
  Google Scholar
• Lewinsohn, D. M., Lewinsohn, D. A. & Grotzke, J. E. TB vaccines at the turn of the century: insights into immunity to M. tuberculosis and modern approaches for prevention of an ancient disease. Semin. Respir. Infect. 18, 320?338 (2003).
  PubMed Google Scholar
• Flynn, J. L. & Chan, J. Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93?129 (2001).
  CAS PubMed Google Scholar
• Jouanguy, E. et al. Interferon- γ-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N. Engl. J. Med. 335, 1956?1961 (1996).
  CAS PubMed Google Scholar
• Jouanguy, E. et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nature Genet. 21, 370?378 (1999).
  CAS PubMed Google Scholar
• Toussirot, E. & Wendling, D. The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother. 5, 581?594 (2004).
  CAS PubMed Google Scholar
• Havlir, D. V. & Barnes, P. F. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 340, 367?373 (1999).
  CAS PubMed Google Scholar
• Cooper, A. M. et al. Disseminated tuberculosis in IFN-γ gene-disrupted mice. J. Exp. Med. 178, 2243?2247 (1993).
  CAS PubMed Google Scholar
• Flynn, J. L. et al. An essential role for IFN-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249?2254 (1993).
  CAS PubMed Google Scholar
• Flynn, J. L. et al. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 89, 12013?12017 (1992).
  CAS PubMed Google Scholar
• Derrick, S. C. et al. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect. Immun. 72, 1685?1692 (2004).
  CAS PubMed PubMed Central Google Scholar
• van Pinxteren, L. A. et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30, 3689?3698 (2000).
  CAS PubMed Google Scholar
• Gonzalez-Juarrero, M. et al. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69, 1722?1728 (2001).
  CAS PubMed PubMed Central Google Scholar
• Ulrichs, T. et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol. 204, 217?228 (2004).
  PubMed Google Scholar
• Teitelbaum, R. et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl Acad. Sci. USA 95, 15688?15693 (1998).
  CAS PubMed Google Scholar
• Sadoff, J. Public private partnership approach to vaccine development. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005).
• Bouneaud, C. et al. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J. Exp. Med. 201, 579?590 (2005).
  CAS PubMed PubMed Central Google Scholar
• Seder, R. A. & Ahmed, R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nature Immunol. 4, 835?842 (2003).
  CAS Google Scholar
• Brewer, T. F. & Colditz, G. A. Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin. Infect. Dis. 20, 126?135 (1995).
  CAS PubMed Google Scholar
• Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698?702 (1994).
  CAS PubMed Google Scholar
• Fine, P. E. M., Carneiro, I. A. M., Milstien, J. B. & Clements, C. J. Issues relating to the use of BCG in immunization programmes (World Health Organization, Geneva, 1999).
• Colditz, G. A. et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96, 29?35 (1995).
  CAS PubMed Google Scholar
• Sterne, J. A., Rodrigues, L. C. & Guedes, I. N. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2, 200?207 (1998).
  CAS PubMed Google Scholar
• Aronson, N. E. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 291, 2086?2091 (2004).
  CAS PubMed Google Scholar
• Fine, P. E. The BCG story: lessons from the past and implications for the future. Rev. Infect. Dis. 11 (Suppl. 2), 353?359 (1989).
  Google Scholar
• Comstock, G. W. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin. Trials 15, 247?276 (1994).
  CAS PubMed Google Scholar
• Soysal, A. et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366, 1443?1451 (2005).
  PubMed Google Scholar
• Tuberculosis Research Centre (ICMR), Chennai. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J. Med. Res. 110, 56?69 (1999).
• Horwitz, M. A. & Harth, G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71, 1672?1679 (2003).
  CAS PubMed PubMed Central Google Scholar
• Horwitz, M. A. et al. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97, 13853?13858 (2000).
  CAS PubMed Google Scholar
• Hoft, D. F. Results of the 1st Phase I trial of a recombinant BCG TB vaccine (rBCG30). Presented at US?Japan Cooperative Medical Science Program; 40th Tuberculosis and Leprosy Research Conference. (Seattle, Washington, 2005).
• Hess, J. et al. Mycobacterium bovis bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Sci. USA 95, 5299?5304 (1998).
  CAS PubMed Google Scholar
• Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86?89 (1998).
  CAS PubMed Google Scholar
• Nasser Eddine, A. & Kaufmann, S. H. E. Improved protection by recombinant BCG. Microbes Infect. 7, 939?946 (2005).
  PubMed Google Scholar
• Grode, L. et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472?2479 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kaufmann, S. H. E. Rational vaccine design against tuberculosis. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005).
• Laufer, A. Managing the transition from academic vaccine research to license oriented development. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005).
• Portnoy, D. A. et al. Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect. Immun. 60, 2710?2717 (1992).
  CAS PubMed PubMed Central Google Scholar
• Edwards, K. M. et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 164, 2213?2219 (2001).
  CAS PubMed Google Scholar
• Kernodle, D. S. Pro-apoptotic BCG vaccine that enhances cellular immune responses and reduces tissue damage. Aeras Global TB Vaccine Foundation Scott Thaler Lecture Series. (Bethesda, Maryland, 2004).
• Jacobs, B. Live attenuated vaccines for TB: Mining the immune evasion function of the tubercle bacillus. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005).
• Chattergoon, M. A. et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nature Biotechnol. 18, 974?979 (2000).
  CAS Google Scholar
• Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818?821 (1997).
  CAS PubMed Google Scholar
• Brosch, R. et al. Comparative genomics of the mycobacteria. Int. J. Med. Microbiol. 290, 143?152 (2000).
  CAS PubMed Google Scholar
• Mahairas, G. G. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178, 1274?1282 (1996).
  CAS PubMed PubMed Central Google Scholar
• Pym, A. S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Med. 9, 533?539 (2003).
  CAS PubMed Google Scholar
• Pym, A. S. et al. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 46, 709?717 (2002).
  CAS PubMed Google Scholar
• Behr, M. A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520?1523 (1999).
  CAS PubMed Google Scholar
• Gordon, S. V. et al. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 32, 643?645 (1999).
  CAS PubMed Google Scholar
• Salamon, H. et al. Detection of deleted genomic DNA using a semiautomated computational analysis of GeneChip data. Genome Res. 10, 2044?2054 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kamath, A. T. et al. In New Live Mycobacterial Vaccines: Defining Essential Steps Towards Clinical Development. (WHO, Geneva, Switzerland, 2004).
  Google Scholar
• Soto, C. Y. et al. IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J. Clin. Microbiol. 42, 212?219 (2004).
  CAS PubMed PubMed Central Google Scholar
• Perez, E. et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol. 41, 179?187 (2001).
  CAS PubMed Google Scholar
• Guleria, I. et al. Auxotrophic vaccines for tuberculosis. Nature Med. 2, 334?337 (1996).
  CAS PubMed Google Scholar
• Smith, D. A. et al. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 69, 1142?1150 (2001).
  CAS PubMed PubMed Central Google Scholar
• Jackson, M. et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67, 2867?2873 (1999).
  CAS PubMed PubMed Central Google Scholar
• Sambandamurthy, V. K. et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun. 73, 1196?1203 (2005).
  CAS PubMed PubMed Central Google Scholar
• Sambandamurthy, V. K. et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nature Med. 8, 1171?1174 (2002).
  CAS PubMed Google Scholar
• Sambandamurthy, V. K. & Jacobs, W. R. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7, 955?961 (2005).
  CAS PubMed Google Scholar
• Andersen, A. B. & Hansen, E. B. Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis. Infect. Immun. 57, 2481?2488 (1989).
  CAS PubMed PubMed Central Google Scholar
• Nagai, S. et al. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect. Immun. 59, 372?382 (1991).
  CAS PubMed PubMed Central Google Scholar
• Young, D. B. & Garbe, T. R. Lipoprotein antigens of Mycobacterium tuberculosis. Res. Microbiol. 142, 55?65 (1991).
  CAS PubMed Google Scholar
• Andersen, P. et al. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 154, 3359?3372 (1995).
  CAS PubMed Google Scholar
• Skjot, R. L. et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. 68, 214?220 (2000).
  CAS PubMed PubMed Central Google Scholar
• Alderson, M. R. et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4+ T cells. J. Exp. Med. 191, 551?560 (2000).
  CAS PubMed PubMed Central Google Scholar
• Dillon, D. C. et al. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J. Clin. Microbiol. 38, 3285?3290 (2000).
  CAS PubMed PubMed Central Google Scholar
• Skeiky, Y. A. et al. T-cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol. 165, 7140?7149 (2000).
  CAS PubMed Google Scholar
• Laal, S. & Skeiky, Y. A. W. In Tuberculosis and the Tubercle Bacillus. (eds Cole, S. T. et al.) 71?83 (American Society for Microbiology Press, Washington DC, 2005).
  Google Scholar
• Skeiky, Y. A. et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect. Immun. 67, 3998?4007 (1999).
  CAS PubMed PubMed Central Google Scholar
• Dillon, D. C. et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect. Immun. 67, 2941?2950 (1999).
  CAS PubMed PubMed Central Google Scholar
• Covert, B. A. et al. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis. Proteomics 1, 574?586 (2001).
  CAS PubMed Google Scholar
• Mattow, J. et al. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis 24, 3405?3420 (2003).
  CAS PubMed Google Scholar
• Mollenkopf, H. J. et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime?Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72, 6471?6479 (2004).
  CAS PubMed PubMed Central Google Scholar
• Huygen, K. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2, 893?898 (1996).
  CAS PubMed Google Scholar
• Baldwin, S. L. et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66, 2951?2959 (1998).
  CAS PubMed PubMed Central Google Scholar
• Skjot, R. L. et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the _esat_-6 gene family. Infect. Immun. 70, 5446?5453 (2002).
  CAS PubMed PubMed Central Google Scholar
• Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618?7628 (2004).
  CAS PubMed Google Scholar
• Weinrich Olsen, A. et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Infect. Immun. 69, 2773?2778 (2001).
  CAS PubMed Google Scholar
• Brandt, L. et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in _M. tuberculosis_-infected guinea pigs. Infect. Immun. 72, 6622?6632 (2004).
  CAS PubMed PubMed Central Google Scholar
• Olsen, A. W. et al. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur. J. Immunol. 30, 1724?1732 (2000).
  CAS PubMed Google Scholar
• Olsen, A. W. et al. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72, 6148?6150 (2004).
  CAS PubMed PubMed Central Google Scholar
• Mazurek, G. H. et al. Comparison of a whole-blood IFN-γ assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286, 1740?1747 (2001).
  CAS PubMed Google Scholar
• Mazurek, G. H. & Villarino, M. E. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 52, 15?18 (2003).
  PubMed Google Scholar
• Dietrich, J. et al. Exchanging ESAT-6 with TB10. 4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT-6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174, 6332?6339 (2005).
  CAS PubMed Google Scholar
• Brooks, J. V. et al. Boosting vaccine for tuberculosis. Infect. Immun. 69, 2714?2717 (2001).
  CAS PubMed PubMed Central Google Scholar
• Goonetilleke, N. P. et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602?1609 (2003).
  CAS PubMed Google Scholar
• Wang, J. et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357?6365 (2004).
  CAS PubMed Google Scholar
• Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of pre-existing adenovirus immunity. J. Virol. 77, 8263?8271 (2003).
  CAS PubMed PubMed Central Google Scholar
• Havenga et al. Novel replication-incompetent adenoviral B-group vectors. J. Virol. (In the press).
• Hone, D. Optimization of nucleic acid vaccine delivery by bacterial vectors. Presented at New Approaches to Vaccine Development. (Sept. 8?10, Berlin, Germany, 2005).
• Schnappinger, D. et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198, 693?704 (2003).
  CAS PubMed PubMed Central Google Scholar
• Voskuil, M. I. et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198, 705?713 (2003).
  CAS PubMed PubMed Central Google Scholar
• Capuano, S. V. et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71, 5831?5844 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hussey, G., Hawkridge, T., Geiter, L. & Hanekom, W. Presented at TB vaccines for the world (April 19?21, Vienna, Austria, 2006).
• McShane, H. et al. Recombinant MVA85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240?1244 (2004).
  CAS PubMed Google Scholar
• Radosevic, K. et al. Presented at TB vaccines for the world (April 19?21, Vienna, Austria, 2006).
  Google Scholar